AI assistant
Flerie AB — Net Asset Value 2025
Apr 3, 2025
6601_rns_2025-04-03_56090d71-893d-4e0c-800b-730888d00a8f.pdf
Net Asset Value
Open in viewerOpens in your device viewer
Press Release
03 April 2025 08:00:00 CEST
FLERIE
NET ASSET VALUE - 31 March 2025
On the 31 March 2025 Flerie AB's Net Asset Value (NAV) was SEK 3.947 million and NAV per share was SEK 50.56.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
|---|---|---|---|---|
| Product Development | ||||
| Prokarium | 42% | 456 | 5.84 | 11.6% |
| Empros Pharma | 79% | 204 | 2.62 | 5.2% |
| Xspray Pharma | 18% | 192 | 2.46 | 4.9% |
| KAHR Medical | 31% | 189 | 2.43 | 4.8% |
| Atrogi | 37% | 176 | 2.25 | 4.4% |
| Lipum | 57% | 170 | 2.17 | 4.3% |
| Xintela | 61% | 162 | 2.08 | 4.1% |
| Microbiotica | 10% | 130 | 1.66 | 3.3% |
| Geneos Therapeutics | 12% | 96 | 1.23 | 2.4% |
| Toleranzia | 66% | 79 | 1.01 | 2.0% |
| Mendus | 24% | 74 | 0.94 | 1.9% |
| AnaCardio | 14% | 69 | 0.89 | 1.8% |
| EpiEndo Pharmaceuticals | 9% | 54 | 0.69 | 1.4% |
| Synerkine Pharma | 43% | 54 | 0.69 | 1.4% |
| Vitara Biomedical | 11% | 50 | 0.64 | 1.3% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.7% |
| Egetis Therapeutics | 2% | 23 | 0.29 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2.270 | 29.08 | 57.5% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.8% |
| Symcel | 31% | 174 | 2.23 | 4.4% |
| Chromafora | 31% | 73 | 0.93 | 1.8% |
| Nanologica | 43% | 48 | 0.61 | 1.2% |
| Frontier Biosolutions | 2% | 18 | 0.23 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Provell Pharmaceuticals* | 72% | 0 | 0.00 | 0.0% |
| Total | 518 | 6.64 | 13.1% | |
| Limited Partnerships, total | 85 | 1.09 | 2.2% | |
| Assets related to Portfolio companies | 262 | 3.35 | 6.6% |
Flerie AB
Skeppsbron 16
111 30 Stockholm
Press Release
03 April 2025 08:00:00 CEST
FLERIE
| Other assets and liabilities | 811 | 10.39 | 20.6% | |
|---|---|---|---|---|
| Net asset value | 3.947 | 50.56 | 100.0% |
- indirect shares in Provell Pharmaceuticals
For more information:
Ted Fjällman, CEO
Email: [email protected]
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
Attachments
NET ASSET VALUE - 31 March 2025
Flerie AB
Skeppsbron 16
111 30 Stockholm